Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

X. Steven Xu, Sam Liao, PhD, Meletios A Dimopoulos, Pieter Sonneveld, MD PhD, P. Joy Ho, Andrew Belch, MD, Merav Leiba, MD, Marcelo Capra, MD PhD, David Gomez, MD, Eva Medvedova, MD, Shinsuke Iida, MD PhD, Chang-Ki Min, MD, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens

Blood (2016) 128 (22): 3340.

https://doi.org/10.1182/blood.V128.22.3340.3340

Published: 2016

Journal Articles

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Christopher P. Venner, MD, Nizar J Bahlis, MD, Paola Neri, MD PhD, Irwindeep Sandhu, MD, Peter Duggan, MD, Andrew Belch, MD, Joanne D Hewitt, RN, BSN, NP, Linda M. Pilarski, PhD, Tatiana Nikitina, Victor H Jimenez-Zepeda, MD

Blood (2015) 126 (23): 4261.

https://doi.org/10.1182/blood.V126.23.4261.4261

Published: 2015

Journal Articles

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Michael P. Chu, MD, Andrew Belch, MD, Lixia Pei, PhD, Xue (Loya) Yang, PhD, Tadeusz Robak, MD PhD, Brendan Rooney, PhD, Andrew Cakana, MD, Helgi van de Velde, MD PhD, Michael B Sawyer, MD

Blood (2015) 126 (23): 1477.

https://doi.org/10.1182/blood.V126.23.1477.1477

Published: 2015

Journal Articles

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Blood (2014) 124 (21): 81.

https://doi.org/10.1182/blood.V124.21.81.81

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 3064.

https://doi.org/10.1182/blood.V124.21.3064.3064

Published: 2014

Journal Articles

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Alexander Klimowicz, PhD, Paola Neri, MD, PhD, Andrew Belch, MD, Michelle Dean, Li Ren, PhD, Kathy Gratton, Jiri Slaby, MD, Jordan Johnson, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 931.

https://doi.org/10.1182/blood.V120.21.931.931

Published: 2012

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

Journal Articles

Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

Donna E. Reece, MD, Giovanni Piza Rodriguez, Andrew Belch, MD, David Szwajcer, MD, FRCP(C), Michael J. Kovacs, MD, FRCPC, Chaim Shustik, MD, Nizar J Bahlis, MD, Darrell J White, MD, Mariela Pantoja, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 1968.

https://doi.org/10.1182/blood.V116.21.1968.1968

Published: 2010

Journal Articles

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Ravi Vij, MBBS, MD, Jonathan L. Kaufman, MD, Andrzej J Jakubowiak, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Kevin T. McDonagh, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Andrew Belch, MD, Frederic J. Reu, MD, Nashat Y Gabrail, MD, Jeffrey Matous, MD, David H. Vesole, MD, PhD, Robert Z. Orlowski, MD, PhD, Mai H. Le, MD, Peter Lee, MD, PhD, Michael Wang, MD, The MMRC

Blood (2010) 116 (21): 1938.

https://doi.org/10.1182/blood.V116.21.1938.1938

Published: 2010

Journal Articles

A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)

Andrew Belch, MD, Atul Sharma, MD, Andrew Spencer, MD, Stefano Tarantolo, Nizar J Bahlis, MD, Dinesh Doval, MD, Gilles Gallant, BPharm, PhD, Elizabeth Kumm, MS, Jerry Klein, PhD, Asher A. Chanan-Khan

Blood (2010) 116 (21): 5031.

https://doi.org/10.1182/blood.V116.21.5031.5031

Published: 2010

Journal Articles

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

A. Keith Stewart, Suzanne Trudel, MD, MSC, FRCPC, Nizar J Bahlis, MD, Darrell J White, MD, Waleed Sabry, MSc, MD, Andrew Belch, MD, Tony Reiman, MD, Jean Roy, MD, FRCPC, Chaim Shustik, MD, Michael J. Kovacs, MD, FRCPC, Jonathan Sussman, Ralph M. Meyer, MD, Erica L Harnett, M.Sc., Danila Oana, Judy A Chapman, Lois Shepherd, MD

Blood (2010) 116 (21): 39.

https://doi.org/10.1182/blood.V116.21.39.39

Published: 2010

Journal Articles

Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients

Carina S. Debes Marun, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 4045.

https://doi.org/10.1182/blood.V116.21.4045.4045

Published: 2010

Journal Articles

Cancer-Specific Nuclear Positioning of Translocation Prone Gene Loci In Non-Malignant B-Cells From Patients with Multiple Myeloma

Lorri D. Martin, Jana Harizanova, PhD, George Zhu, Andrew Belch, MD, Sabine Mai, PhD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 783.

https://doi.org/10.1182/blood.V116.21.783.783

Published: 2010

Journal Articles

Second Clones In Molecularly-Defined Biclonal Multiple Myeloma Are Derived From Unrelated B Cells, Can Be Present at High Frequency and Exhibit Chromosomal Abnormalities

Jitra Kriangkum, PhD, Carina Debes Marun, BSc, Sarah Motz, BSc, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 2981.

https://doi.org/10.1182/blood.V116.21.2981.2981

Published: 2010

Journal Articles

Molecular Biclonality: Analysis of Clonotypic IgH VDJ Reveals the Frequent Occurrence of a Second Clone in Multiple Myeloma.

Jitra Kriangkum, PhD, Sarah Motz, BSc, Carina Debes Marun, BSc, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2009) 114 (22): 1813.

https://doi.org/10.1182/blood.V114.22.1813.1813

Published: 2009

Journal Articles

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

David Siegel, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Melissa Alsina, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Nizar J Bahlis, MD, Chaim Shustik, MD, Mai H. Le, MD, Lori Kunkel, MD, Mark K Bennett, PhD, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 303.

https://doi.org/10.1182/blood.V114.22.303.303

Published: 2009

Journal Articles

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Inka Toman, M.Sc., Jonathan Loree, Alex Klimowicz, Ph.D., Nizar J Bahlis, MD, Raymond Lai, MD, PhD, Andrew Belch, MD, Linda M. Pilarski, PhD, Tony Reiman, MD

Blood (2009) 114 (22): 2822.

https://doi.org/10.1182/blood.V114.22.2822.2822

Published: 2009

Journal Articles

Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.

Maurizio Zangari, MD, Latha Polavaram, M.D., Fenghuang Zhan, MD, PhD, Guido J. Tricot, Ravi Vij, MD, Sundar Jagannath, MD, David Siegel, A. Keith Stewart, MBChB, Luhua Wang, Robert Z Orlowski, M.D., Ph.D., Andrew Belch, MD, Andrzej J Jakubowiak, MD, PhD, George Somlo, MD, Suzanne Trudel, MD, Nizar J Bahlis, MD, Sagar Lonial, MD, Seema Singhal, MD, Vishal Kukreti, MD, FRCPC

Blood (2009) 114 (22): 2865.

https://doi.org/10.1182/blood.V114.22.2865.2865

Published: 2009

Journal Articles

Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance.

Hemalatha Kuppusamy, Amanda Warkentin, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2009) 114 (22): 2841.

https://doi.org/10.1182/blood.V114.22.2841.2841

Published: 2009

NARROW

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients

Cancer-Specific Nuclear Positioning of Translocation Prone Gene Loci In Non-Malignant B-Cells From Patients with Multiple Myeloma

Second Clones In Molecularly-Defined Biclonal Multiple Myeloma Are Derived From Unrelated B Cells, Can Be Present at High Frequency and Exhibit Chromosomal Abnormalities

Molecular Biclonality: Analysis of Clonotypic IgH VDJ Reveals the Frequent Occurrence of a Second Clone in Multiple Myeloma.

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.

Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only